Subarachnoid extension of intracerebral hemorrhage and 90-day outcomes in INTERACT2

Guofang Chen; Hisatomi Arima; Guojun Wu; Emma Heeley; Candice Delcourt; Peiying Zhang; Alejandro A. Rabinstein; Thompson Robinson; Christian Stapf; Yining Huang; Lili Song; Jie Yang; Xia Wang; Qiang Li; X. Chen; John Chalmers; Craig Anderson; INTERACT2 Investigators

doi:10.1161/Strokeaha.113.003524

Subarachnoid extension of intracerebral hemorrhage and 90-day outcomes in INTERACT2

Guofang Chen, Hisatomi Arima, Guojun Wu, Emma Heeley, Candice Delcourt, Peiying Zhang, Alejandro A. Rabinstein, Thompson Robinson, Christian Stapf, Yining Huang, Lili Song, Jie Yang, Xia Wang, Qiang Li, X. Chen, John Chalmers, Craig Anderson, INTERACT2 Investigators

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Abstract

Background and Purpose— The prognostic significance of subarachnoid extension of intracerebral hemorrhage was determined in the INTEnsive blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT2) study.

Methods— INTERACT2 was an open randomized controlled trial of early intensive compared with guideline-recommended blood pressure lowering in patients with elevated systolic blood pressure within 6 hours of intracerebral hemorrhage. Independent predictors of death or major disability (scores 3–6 on the modified Rankin Scale) at 90 days were analyzed in logistic regression models.

Results— Of 2582 participants, 192 (7%) had subarachnoid extension, which was associated with larger hematoma volumes (P<0.0001) and higher National Institute of Health Stroke Scale score (P<0.0001). Subarachnoid extension predicted death or major disability at 90 days (71% versus 53%; unadjusted odds ratio, 2.25; 95% confidence interval, 1.63–3.10; P<0.0001). The association remained significant after adjusting for age, region, lipid-lowering therapy, systolic blood pressure, glucose, location of hematoma, intraventricular extension, and randomized treatment (odds ratio, 2.17; 95% confidence interval, 1.50–3.14; P<0.0001), but not after further adjustment for baseline hematoma volume (P=0.62).

Conclusions— Subarachnoid extension of intracerebral hemorrhage is associated with poor prognosis, which is determined by a larger volume of the underlying intraparenchymal hematoma.

Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00716079.

Original language	English
Pages (from-to)	258-260
Number of pages	3
Journal	Stroke
Volume	45
Issue number	1
DOIs	https://doi.org/10.1161/Strokeaha.113.003524
Publication status	Published - 2014
Externally published	Yes

Keywords

assessment, outcomes
cerebral hemorrhage
clinical trial

Access to Document

10.1161/Strokeaha.113.003524

Cite this

Chen, G., Arima, H., Wu, G., Heeley, E., Delcourt, C., Zhang, P., Rabinstein, A. A., Robinson, T., Stapf, C., Huang, Y., Song, L., Yang, J., Wang, X., Li, Q., Chen, X., Chalmers, J., Anderson, C., & INTERACT2 Investigators (2014). Subarachnoid extension of intracerebral hemorrhage and 90-day outcomes in INTERACT2. Stroke, 45(1), 258-260. https://doi.org/10.1161/Strokeaha.113.003524

@article{ce3d4cf3ffc140b880a95bdfecae01f9,

title = "Subarachnoid extension of intracerebral hemorrhage and 90-day outcomes in INTERACT2",

abstract = "Background and Purpose— The prognostic significance of subarachnoid extension of intracerebral hemorrhage was determined in the INTEnsive blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT2) study. Methods— INTERACT2 was an open randomized controlled trial of early intensive compared with guideline-recommended blood pressure lowering in patients with elevated systolic blood pressure within 6 hours of intracerebral hemorrhage. Independent predictors of death or major disability (scores 3–6 on the modified Rankin Scale) at 90 days were analyzed in logistic regression models. Results— Of 2582 participants, 192 (7\%) had subarachnoid extension, which was associated with larger hematoma volumes (P<0.0001) and higher National Institute of Health Stroke Scale score (P<0.0001). Subarachnoid extension predicted death or major disability at 90 days (71\% versus 53\%; unadjusted odds ratio, 2.25; 95\% confidence interval, 1.63–3.10; P<0.0001). The association remained significant after adjusting for age, region, lipid-lowering therapy, systolic blood pressure, glucose, location of hematoma, intraventricular extension, and randomized treatment (odds ratio, 2.17; 95\% confidence interval, 1.50–3.14; P<0.0001), but not after further adjustment for baseline hematoma volume (P=0.62). Conclusions— Subarachnoid extension of intracerebral hemorrhage is associated with poor prognosis, which is determined by a larger volume of the underlying intraparenchymal hematoma. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00716079.",

keywords = "assessment, outcomes, cerebral hemorrhage, clinical trial",

author = "Guofang Chen and Hisatomi Arima and Guojun Wu and Emma Heeley and Candice Delcourt and Peiying Zhang and Rabinstein, \{Alejandro A.\} and Thompson Robinson and Christian Stapf and Yining Huang and Lili Song and Jie Yang and Xia Wang and Qiang Li and X. Chen and John Chalmers and Craig Anderson and \{INTERACT2 Investigators\}",

year = "2014",

doi = "10.1161/Strokeaha.113.003524",

language = "English",

volume = "45",

pages = "258--260",

journal = "Stroke",

issn = "0039-2499",

publisher = "Wolters Kluwer Health",

number = "1",

}

Chen, G, Arima, H, Wu, G, Heeley, E, Delcourt, C, Zhang, P, Rabinstein, AA, Robinson, T, Stapf, C, Huang, Y, Song, L, Yang, J, Wang, X, Li, Q, Chen, X, Chalmers, J, Anderson, C & INTERACT2 Investigators 2014, 'Subarachnoid extension of intracerebral hemorrhage and 90-day outcomes in INTERACT2', Stroke, vol. 45, no. 1, pp. 258-260. https://doi.org/10.1161/Strokeaha.113.003524

TY - JOUR

T1 - Subarachnoid extension of intracerebral hemorrhage and 90-day outcomes in INTERACT2

AU - Chen, Guofang

AU - Arima, Hisatomi

AU - Wu, Guojun

AU - Heeley, Emma

AU - Delcourt, Candice

AU - Zhang, Peiying

AU - Rabinstein, Alejandro A.

AU - Robinson, Thompson

AU - Stapf, Christian

AU - Huang, Yining

AU - Song, Lili

AU - Yang, Jie

AU - Wang, Xia

AU - Li, Qiang

AU - Chen, X.

AU - Chalmers, John

AU - Anderson, Craig

AU - INTERACT2 Investigators

PY - 2014

Y1 - 2014

N2 - Background and Purpose— The prognostic significance of subarachnoid extension of intracerebral hemorrhage was determined in the INTEnsive blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT2) study. Methods— INTERACT2 was an open randomized controlled trial of early intensive compared with guideline-recommended blood pressure lowering in patients with elevated systolic blood pressure within 6 hours of intracerebral hemorrhage. Independent predictors of death or major disability (scores 3–6 on the modified Rankin Scale) at 90 days were analyzed in logistic regression models. Results— Of 2582 participants, 192 (7%) had subarachnoid extension, which was associated with larger hematoma volumes (P<0.0001) and higher National Institute of Health Stroke Scale score (P<0.0001). Subarachnoid extension predicted death or major disability at 90 days (71% versus 53%; unadjusted odds ratio, 2.25; 95% confidence interval, 1.63–3.10; P<0.0001). The association remained significant after adjusting for age, region, lipid-lowering therapy, systolic blood pressure, glucose, location of hematoma, intraventricular extension, and randomized treatment (odds ratio, 2.17; 95% confidence interval, 1.50–3.14; P<0.0001), but not after further adjustment for baseline hematoma volume (P=0.62). Conclusions— Subarachnoid extension of intracerebral hemorrhage is associated with poor prognosis, which is determined by a larger volume of the underlying intraparenchymal hematoma. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00716079.

AB - Background and Purpose— The prognostic significance of subarachnoid extension of intracerebral hemorrhage was determined in the INTEnsive blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT2) study. Methods— INTERACT2 was an open randomized controlled trial of early intensive compared with guideline-recommended blood pressure lowering in patients with elevated systolic blood pressure within 6 hours of intracerebral hemorrhage. Independent predictors of death or major disability (scores 3–6 on the modified Rankin Scale) at 90 days were analyzed in logistic regression models. Results— Of 2582 participants, 192 (7%) had subarachnoid extension, which was associated with larger hematoma volumes (P<0.0001) and higher National Institute of Health Stroke Scale score (P<0.0001). Subarachnoid extension predicted death or major disability at 90 days (71% versus 53%; unadjusted odds ratio, 2.25; 95% confidence interval, 1.63–3.10; P<0.0001). The association remained significant after adjusting for age, region, lipid-lowering therapy, systolic blood pressure, glucose, location of hematoma, intraventricular extension, and randomized treatment (odds ratio, 2.17; 95% confidence interval, 1.50–3.14; P<0.0001), but not after further adjustment for baseline hematoma volume (P=0.62). Conclusions— Subarachnoid extension of intracerebral hemorrhage is associated with poor prognosis, which is determined by a larger volume of the underlying intraparenchymal hematoma. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00716079.

KW - assessment, outcomes

KW - cerebral hemorrhage

KW - clinical trial

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84893674852&partnerID=MN8TOARS

UR - https://www.scopus.com/pages/publications/84893674852

U2 - 10.1161/Strokeaha.113.003524

DO - 10.1161/Strokeaha.113.003524

M3 - Article

SN - 0039-2499

VL - 45

SP - 258

EP - 260

JO - Stroke

JF - Stroke

IS - 1

ER -

Subarachnoid extension of intracerebral hemorrhage and 90-day outcomes in INTERACT2

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this